Richard Porter brings over 20 years of experience working across multiple therapeutic areas in the pharmaceutical and biotech industries.
Prior to joining Corlieve, Richard was the COO of Therachon until the acquisition by Pfizer. Previously he was at Roche in positions of increasing responsibility, most recently as the Global Head of Scientific Business Strategy and Operations Management for Neuroscience Ophthalmology and Rare Diseases directing the strategic and operational activities of the department. He has also served as a Product General Manager of the Emerging Business Unit at Shire Pharmaceuticals, and held scientific leadership positions at Vernalis and ASTRA. Richard received his academic training at the University of Southampton, the University of Oxford (United Kingdom) and at the University of Rochester (United States).
Jeetendra Bhatia has over 20 years of experience in pharmaceutical development & cGMP manufacturing. His areas of expertise include development of novel therapeutics, gene therapy and cGMP manufacture, and Pharmaceutical Supply Chain.
Jeet has developed both recombinant and microbial treatments for cancer and infectious diseases and has published several scientific articles. He completed his PhD in 1999 at the University of London while working as Head of Production for Cancer Research UK, Department of Oncology at The Royal Free Hospital. Jeet has held several roles in industry, including Senior Development Manager at Avidex Ltd, and Head of Process & Analytical Development at Emergent BioSolutions. From 2011 to 2016 Jeet was PsiOxus Therapeutic’s VP of Pharmaceutical Development where he developed a cGMP process for a unique adenovirus oncolytic therapeutic vaccine. Prior to joining Corlieve Jeet was the CMC Project Director for Freeline Therapeutics where he managed the AAV (Adeno-Associated Virus) gene therapy manufacturing platform.
Formerly Clinical Program Leader CNS, Translational Medicine Expert in Neuroscience at Boehringer Ingelheim.
Extensive experience designing clinical development strategies, conduct of clinical studies and biomarker studies in neurology and other therapeutic areas involving different therapeutic modalities including gene therapy.
Trained Neurologist and neuropaediatrician.
Formerly head of project leadership and business operations at Roche neuroscience and rare diseases R&D.
Over 25 years experience in both operative and strategic roles in Pharma, leading projects across multiple modalities and disease areas.
Founding member of Roche’s academic alliance group responsible for global strategic collaborations. Former global head procurement research services and R&D business partner.
PhD in biochemistry and genetics complemented with business training from London Business School and IMD, Lausanne.